Less Ads, More Data, More Tools Register for FREE

Pin to quick picksItaconix Plc Regulatory News (ITX)

Share Price Information for Itaconix Plc (ITX)

Share Price is delayed by 15 minutes
Get Live Data
113.50    0.00 (0.00%)
Bid:
110.00
Ask:
117.00
Spread: 7.00 (6.364%)
Market Cap: £15.31m
ITX Live PriceLast checked at - London Stock Exchange

Intraday Itaconix Plc Share Chart

Full Year Trading Update

13 Jan 2026 07:00

RNS Number : 5928O
Itaconix PLC
13 January 2026
 

For release: 07.00, 13 January 2026

Itaconix plc

("Itaconix" or the "Company")

Full Year Trading Update

Record revenues exceeding $10 million for the first time, driven by third consecutive record half year and strong customer momentum

Itaconix plc (AIM: ITX) (OTCQB: ITXXF), a leading innovator in high-performance plant-based specialty polymers, is pleased to provide a trading update for the year ended 31 December 2025.

Unaudited revenues for FY 2025 increased 59% year-on-year to $10.3 million (FY 2024: $6.5 million), exceeding $10 million for the first time. This performance was underpinned by a third consecutive record half year, with revenues of $5.5 million in H2 2025, up from $4.8 million in H2 2024.

Revenue growth was generated across both existing and new customers, spanning major applications and geographies. Demand for the Company's patented plant-based polymers continued to strengthen as global consumer product manufacturers increasingly adopt sustainable, high-performance ingredients to enhance formulation performance and deliver added value in detergent, hygiene and beauty products. This growth in revenue and a step change in the Company's commercial traction have enabled Itaconix to invest further in demand generation and support for 2026.

The Board remains optimistic about the Company's prospects for 2026 and believes that Itaconix is well positioned to deliver continued revenue growth, supported by a growing customer pipeline, expanding product adoption and a scalable, capital-efficient operating model. 

Further details on 2025 trading performance and the outlook for 2026 will be provided with the Company's FY 2025 results, expected in late March 2026.

John R. Shaw, CEO of Itaconix, commented:

"2025 was a milestone year for Itaconix. Delivering record revenues of over $10 million for the first time, alongside our third consecutive record half year, demonstrates the accelerating commercial momentum behind our technology and customer proposition.

"We are seeing growing validation from both new and existing customers as our plant-based specialty polymers become embedded in next-generation consumer products where performance, sustainability and value are all critical.

"Entering 2026, Itaconix is operating from a position of strength: we are well funded, capital efficient and supported by a deep and expanding revenue pipeline. With increasing scale, disciplined execution and strong customer engagement, we believe the Company is firmly on track towards building a large, profitable and enduring specialty ingredients business, delivering long-term value for shareholders."

- ends -

Enquiries:

Itaconix plc +1 603 775 4400

John R. Shaw / Laura Denner

Rosewood +44 (0) 207 653 8704

Financial PR

John West / Llewellyn Angus / Lily Pearce

Canaccord Genuity +44 (0) 7523 8000

Nominated Adviser and Broker

Adam James / Harry Pardoe

 

About Itaconix

Itaconix uses its proprietary plant-based polymer technology platform to produce and sell specialty ingredients that improve the safety, performance, and sustainability of consumer products. The Company's current ingredients are enabling and leading new generations of cost-effective, decarbonized consumer products in home and personal care.

www.itaconix.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBIGDBXBBDGLD
Date   Source Headline
4th Apr 20177:00 amRNSPreliminary Results Announcement - Replacement
27th Mar 20177:00 amRNSFinal Results
1st Mar 20177:00 amRNSChange of Name to Itaconix plc
10th Feb 20177:00 amRNSHolding(s) in Company
1st Feb 20171:33 pmRNSTotal Voting Rights
27th Jan 201711:53 amRNSJoint development agreement with AkzoNobel
23rd Jan 20177:00 amRNSExclusive Supply & Marketing Agreement with Croda
9th Jan 20177:00 amRNSBlock listing Interim Review
3rd Jan 20177:00 amRNSChange of Adviser
30th Dec 20169:22 amRNSDirectorate Change
2nd Nov 20161:18 pmRNSDivestment of Nicotine Gum Business
14th Oct 20167:00 amRNSDirector/PDMR Shareholding
6th Oct 20167:00 amRNSDirector/PDMR Shareholding
30th Sep 20167:00 amRNSDirector/PDMR Shareholding
22nd Sep 20167:00 amRNSInterim Results
19th Sep 20167:00 amRNSDivestment of Nicotine Gum Business
13th Sep 201611:34 amRNSDirectorate Change
7th Sep 20167:00 amRNSFirst Commercial Sales of Itaconix® CHTT
1st Aug 201611:33 amRNSTotal Voting Rights
15th Jul 20168:04 amRNSHolding(s) in Company
11th Jul 20164:34 pmRNSHolding(s) in Company
11th Jul 20163:35 pmRNSBlock listing Interim Review
8th Jul 201611:55 amRNSResult of General Meeting
8th Jul 20167:00 amRNSSuccessful Application for Accelerated Whitewash
22nd Jun 20164:29 pmRNSPosting of Circular and Notice of General Meeting
21st Jun 20162:24 pmRNSResults of Placing
21st Jun 20167:00 amRNSAcquisition & Placing
20th Jun 20165:31 pmRNSAcquisition & Placing
19th May 20162:33 pmRNSResult of AGM
19th May 20167:00 amRNSAGM Statement
7th Apr 20167:00 amRNSNotice of AGM & Posting of Annual Report
1st Apr 20167:00 amRNSTotal Voting Rights
21st Mar 20167:00 amRNSFinal Results
16th Mar 20167:00 amRNSDirectorate Change
1st Mar 20168:41 amRNSTotal Voting Rights
25th Jan 20167:00 amRNSRenewed & Expanded Contract
11th Jan 20167:00 amRNSBlocklisting Interim Review
30th Nov 20155:21 pmRNSHolding(s) in Company
30th Nov 20157:00 amRNSTotal Voting Rights
30th Oct 201512:30 pmRNSTotal Voting Rights
21st Sep 20157:00 amRNSInterim Results
18th Sep 20157:00 amRNSDirectorate Change
7th Sep 201512:18 pmRNSTotal Voting Rights
2nd Sep 20157:00 amRNSBlocklisting Interim Review
1st Sep 20157:03 amRNSLicence with OCI Alabama LLC
15th Jun 201512:27 pmRNSHolding(s) in Company
3rd Jun 20157:00 amRNSGlobal licence signed with Solvay
20th May 201512:17 pmRNSResult of AGM
15th May 20151:21 pmRNSHolding(s) in Company
15th May 20151:17 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.